MedTech Spectrum

Article Name China

International Healthcare Week Opens, Fuelling Healthcare Breakthroughs

The summit convenes over 90 influential international healthcare officials, research and medical experts, start-ups, investors

12th May, 2026

Chance Pharma’s CXG87 Moves Into China Regulatory Review for Asthma Treatment

The NMPA acceptance of Chance Pharma’s first new drug application advances CXG87, an improved budesonide/formoterol dry powder inhalation therapy, toward potential commercialisation in China.

08th May, 2026

Hangzhou Diagens Biotechnology Unveils DoctorBench Medical AI Evaluation Platform

The platform’s creation is rooted in nearly a decade of deep collaboration by a cross-disciplinary team

04th May, 2026

China Medical System Secures Exclusive China Rights for IV Iron Therapies from Pharmacosmos A/S

Both IV iron therapies are originator products already approved in China and included in the National Reimbursement Drug List (NRDL)

27th April, 2026

Everest Medicines Announces Positive First-in-Human Data for Personalised mRNA Cancer Vaccine EVM16 at AACR 2026

Demonstrating a Favourable Safety Profile, Robust Immunogenicity, and Promising Preliminary Efficacy

23rd April, 2026

Datasea Completes $1.01M AI Multimodal Projects to Advance High-Margin Digital Solutions Strategy

Delivery of three projects highlights growing adoption of AI-driven, scenario-based applications across enterprise and digital services

21st April, 2026

CStone Reveal Preclinical Data on Next-Generation ADCs Targeting EGFR/HER3 and Tumor Heterogeneity

CStone presents preclinical data on three differentiated antibody-drug conjugates, including a dual-target EGFR/HER3 candidate

20th April, 2026

HighTide Therapeutics Appoints Veteran CMO as HTD1801 Signals Breakthrough Potential in CKD

He played a key role in the development strategy for dapagliflozin, a leading SGLT-2 inhibitor that has become a global blockbuster in the treatment of metabolic diseases

03rd April, 2026

CanSino Biologics Returns to Profitability in 2025 as Vaccine Portfolio Drives Growth

The strengthening of routine vaccine sales has contributed to a more balanced revenue mix and enhanced earnings visibility

03rd April, 2026

Everest Medicines Enters into Asset Purchase Agreement for Etripamil Nasal Spray

The Company has acquired the rights to develop, manufacture, and commercialise CARDAMYST (etripamil) nasal spray in Greater China

24th March, 2026

Everest Medicines Launches VELSIPITY in Mainland China

VELSIPITY(R) was approved for marketing by China’s National Medical Products Administration (NMPA) in February this year

13th March, 2026

Fangzhou and Youcare Pharmaceutical Group Form Alliance to Advance AI-Driven Chronic Care Services

The agreement outlines a joint commitment to applying AI across various chronic care scenarios and upgrading full-lifecycle health management solutions

02nd March, 2026

Scaling the WHO Screen-and-Treat Model across China’s Tiered Healthcare System

In this evolving landscape, PHASE Scientific’s exclusive partnership with Liger Medical signals a strategic shift toward portable, community-deployable cervical care solutions

12th February, 2026

Everest Medicines Announces China NMPA Approval of VELSIPITY(R) for Adults

The approval was based on results from the Asian multicenter Phase 3 ENLIGHT UC study (ES101002) and the global ELEVATE UC Phase 3 program (ELEVATE UC 52 and ELEVATE UC 12)

09th February, 2026

Lishan Biotech Bets on Microbiome Immunotherapy BMC128

BMC128 was developed by Biomica, Evogene’s subsidiary, and is currently completing a Phase 1 clinical study, showing promising early clinical results

06th February, 2026

PHASE Scientific Expands Cervical Health Portfolio with China Distributorship of Liger Medical’s Portable Cervical Treatment

This partnership with Liger Medical reflects our commitment to bringing leading global innovation into China’s healthcare system

05th February, 2026

ZEISS announces NMPA approval in China for powerful ophthalmic microscopes, enhancing surgical visualisation

The ZEISS ARTEVO 750 ophthalmic microscope is another breakthrough in ZEISS's ophthalmic surgical microscope family that made its Chinese debut at the 2025 China International Import Expo (CIIE)

03rd February, 2026